All the news

COVID-19 has caused substantial disruption to viral hepatitis screening and treatment, a global survey finds, but has also led to improvements in laboratory capacity and telemedicine that will benefit future efforts to eliminate ...

People with hepatitis C were more likely to be admitted to hospital as a result of SARS-CoV-2 infection but no more likely to die when compared to people without hepatitis C of ...

People with decompensated cirrhosis should be prioritised for COVID-19 vaccination and immunosuppressive treatment after a liver transplant should not be a barrier to vaccination, an international panel of liver experts has concluded. Their review ...

Fatty liver disease combined with obesity places people at much higher risk of severe COVID-19, analysis of British people who tested positive for SARS-CoV-2 shows. Obesity alone did not increase the risk ...

Decompensated cirrhosis, alcoholic liver disease and hepatocellular carcinoma each raise the risk of death and severe illness from COVID-19 among people with chronic liver disease, but other liver conditions do not, a US ...

People with advanced liver cirrhosis are more likely to develop severe COVID-19 complications and to die from it, but those who have received liver transplants do not appear to be at greater ...

The European Association for the Study of the Liver (EASL) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) have updated their guidance on chronic liver disease and COVID-19, issued in ...

Hepatitis elimination efforts are being severely affected by the COVID-19 pandemic in many settings, results of a 32-country survey by the World Hepatitis Alliance show. The survey of civil society hepatitis organisations and frontline ...

Increases in liver enzymes are common in people with COVID-19 and occur more frequently in people with severe COVID-19, a meta-analysis of studies published in Hepatology International shows. Most liver enzyme elevations were ...

Sofosbuvir and daclatasvir, two antiviral drugs used to treat hepatitis C, were associated with faster recovery, shorter hospitalisation and improve survival among people with moderate or severe COVID-19, researchers reported this month at the ...